- Mereo BioPharma said it had been granted a fast-track designation by the US Food and Drug Administration for an ovarian cancer treatment.

The status was given to navicixizumab for the treatment of high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who had received at least three prior therapies and/or prior bevacizumab.

Navicixizumab was an anti-DLL4/VEGF bispecific antibody and one of two product candidates Mereo acquired through its April 2019 merger with OncoMed Pharmaceuticals.

At 1:10pm: [LON:MPH] Mereo Biopharma Group Ltd share price was +6p at 65.5p

Story provided by